***HIST1H1E* Heterozygous Protein Truncating Variants Cause a Recognizable Syndrome with Intellectual Disability and Distinctive Facial Gestalt: A Study to Clarify the HIST1H1E Syndrome Phenotype in 30 individuals.**

Deepika D’Cunha Burkardt1 , Anna Zachariou2, Chey Loveday2, Clare L Allen3, David J. Amor4, Anna Ardissone5, Siddharth Banka6,7, Alexia Bourgois8, Christine Coubes9, Cheryl Cytrynbaum10, Laurence Faivre11, Gerard Marion12, Rachel Horton13, Dieter Kotzot14, Guillermo Lay-Son15, Melissa Lees16, Karen Low17, Ho-Ming Luk18, Paul Mark19, Allyn McConkie-Rosell20, Marie McDonald MD20, John Pappas21, Christophe Phillipe22, Deborah Shears23, Brian Skotko24, Fiona Stewart25, Helen Stewart26, I Karen Temple27, Frederic Tran Mau-Them28, Ricardo A. Verdugo29, Rosanna Weksberg10, Yuri A. Zarate30, John M Graham31, Katrina Tatton-Brown2,32,33\*

1: University Hospitals Rainbow Babies and Children, Cleveland, OH /Case Western Reserve University, Cleveland, OH, USA

2: Institute of Cancer Research, London, UK

3: Lowerbank Dental Practice, Leyland, UK

4: Murdoch Children’s Research Institute and University of Melbourne Department of Paediatrics, The Royal Children's Hospital, Parkville, Victoria, Australia

5: Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy

6: Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
7: Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, U.K.

8: CHU Côte de Nacre, Service de Génétique, Caen, Fr

9: Hôpital Arnaud de Villeneuve Montpellier, Fr

10: The Hospital for Sick Children, Div of Clinical and Metabolic Genetics, Toronto, ON, CA

11: Genetics center, Genetics, Hôpital d'Enfants, Dijon, FR

12: Centre Hospitalier Universitaire de Caen Normandie, Service de génétique
Caen, FR

13: University Hospital Southampton NHS Foundation Trust Southampton, Southampton, UK

14: Division of Clinical Genetics, Department of Pediatrics, Paracelsus Medical University Salzburg, Salzburg, Austria.

15: Pontificia Universidad Católica de Chile, División de Pediatría, Santiago, CL

16: Great Ormond Street Hospital For Children NHS Foundation Trust, Clinical Genetics department, London, UK

17: University Hospitals Bristol, Clinical Genetics, St Michaels Hospital, Southwell Street
Bristol, Bristol, UK

18: Department of Health, Clinical Genetic Service, Hong Kong, HK

19: Spectrum Health Division of Medical Genetics, Grand Rapids, MI, USA

20: Duke University Medical Genetics, Department of Pediatrics, Division of Medical Genetics, Durham, NC, USA

21: New York University School of Medicine, Human Genetics Program New York, NY, USA

22: UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, and INSERM UMR1231 GAD, F-21000, Dijon, France

23: Churchill Hospital, Clinical Genetics, Oxford, UK

24: Division of Medical Genetics and Genomics, Department of Pediatrics, Massachusetts General Hospital, Boston, USA and Department of Pediatrics, Harvard Medical School, Boston, USA

25: Belfast City Hospital, Medical Genetics, Belfast, UK

26: Oxford University Hospitals NHS Foundation Trust, clinical genetics, Oxford Centre for Genomic Medicine ACE building Nuffield Orthopaedic Centre Oxford University Hospitals NHS Foundation Trust Windmill Road Headington, Oxford, UK

27: Faculty of Medicine, University of Southampton and Wessex Clinical Genetics Service, University Hospital Southampton, Southampton, UK

28: Centre Hospitalier Universitaire de Dijon, FHU TRANSLAD, Dijon, Bourgogne, FR / Centre Hospitalier Universitaire de Dijon, UF d’innovation en génétique moléculaire, Plateau technique de biologie, CHU, Dijon, FR

29: ICBM, Programa de Genética Humana, Santiago, CL

30: Arkansas Children's Hospital, Section of Genetics and Metabolism, Little Rock, AR, USA

31: Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

32. South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK

33: St George's University of London, London, UK.

\* denotes Corresponding Author

**Abstract**

*Histone Gene Cluster 1, Member E,* *HIST1H1E,* encodes histone H1.4 and is one of a family of epigenetic regulator genes that acts as a linker histone protein and is responsible for higher order chromatin structure. HIST1H1E syndrome (also known as Rahman syndrome, OMIM #617537) is a recently described intellectual disability syndrome. 3 different heterozygous truncating mutations in the HIST1H1E gene were reported in 5 patients with intellectual disability and height and/or head circumference equal to or greater than +2SD. Since the initial description of five unrelated individuals with three different heterozygous protein truncating variants (PTVs) in the *HIST1H1E* gene in 2017, we have recruited 30 patients, all with *HIST1H1E* PTVs that result in the same shift in frame and that cluster to a 94 base pair region in the *HIST1H1E* carboxy terminal domain (CTD). The identification of 30 patients with *HIST1H1E* variants has allowed the clarification of the HIST1H1E syndrome phenotype. Major findings include an intellectual disability and a recognizable facial appearance. Intellectual disability was reported in all patients and is most frequently of moderate severity. The facial gestalt consists of a high frontal hairline and full lower cheeks in early childhood and, in later childhood and adulthood, affected individuals have a strikingly high frontal hairline, frontal bossing and deep-set eyes. Other associated clinical features include hypothyroidism, abnormal dentition, behavioral issues, cryptorchidism and cardiac anomalies. Brain MRI imaging is frequently abnormal with a slender corpus callosum a frequent finding.

**Keywords:** *HIST1H1E*, intellectual disability, Epigenetic regulator gene, Rahman Syndrome

**Introduction**

HIST1H1E syndrome (also known as Rahman syndrome, OMIM #617537) is a recently described intellectual disability syndrome caused by protein truncating variants (PTVs) in the *Histone Gene Cluster 1, Member E,* *HIST1H1E* (Tatton-Brown et al., 2017). *HIST1H1E*, is located at chromosome 6p22.2 and encodes the ubiquitously expressed human linker Histone H1.4, one of a family of linker histones that has historically been thought to determine higher order chromatin structure facilitating DNA replication, DNA repair and genome stability (Fyodorov et al., 2018). More specifically, Histone H1.4 is preferentially sequestered to heterochromatin regions: in the presence of Histone H1.4, nucleosome arrays arrange into a twisted left-hand double helix with a zig-zag two-start tetranucleosome (Roque et al., 2016, Song et al., 2014, Ponte et al., 2017, McGinty et al., 2015).

Since the HIST1H1E syndrome was first described as an intellectual disability syndrome (in association with increased growth) in 2017, a total of seven patients have been reported (Tatton-Brown et al. 2017; Takenouchi et al., 2018; Duffney et al., 2018). Here we describe 30 patients with HIST1H1E syndrome with 14 different pathogenic variants, all PTVs causing the same shift in frame and clustering to a 94 base pair region in the *HIST1H1E* carboxy terminal domain. Through a detailed clinical evaluation of these 30 patients, we describe a recurrent and recognizable HIST1H1E syndrome phenotype characterized by a distinctive facial appearance and moderate intellectual disability in association with a range of medical problems.

**Subjects and Methods**

The study was approved by the UK Research Ethics Committee (10/H0305/83), granted by the Cambridge South Research Ethics Committee and the London Multicentre Research Ethics Committee (MREC MREC/01/2/44). Thirty patients with *HIST1H1E* variants, identified through exome sequencing in the diagnostic and research environments, were recruited through clinical genetics services worldwide and family support groups (https://www.facebook.com/hist1h1e/) (including five previously reported patients, Tatton-Brown et al., 2017, and one patient included in a paper submitted for publication, details in supplementary table 1). The *HIST1H1E* variants were reported with reference to the canonical transcript (NM\_005321.2). Informed consent was obtained from all participants and/or parents. Photographs, with accompanying written informed consent to publish, were requested from all participants and received from 21.

Detailed phenotype data were collected through clinic evaluation by at least one of the authors (all experienced dysmorphologists) and standardized clinical proformas. Growth parameter standard deviations were calculated with reference to UK90 growth data (Cole et al., 2012). Intellectual disability was classified by the recruiting clinician as mild, moderate, or severe and unclassified where a child was demonstrating developmental delay but was judged by the clinician as being too young to determine the severity of the intellectual disability. For the purposes of our study the following working definitions were used: mild intellectual disability typically described where an individual had delayed milestones but would attend a mainstream school with some support and live independently, with support, as an adult; moderate intellectual disability typically described where an individual required high-level support in a mainstream school or special educational needs schooling and would live with support as an adult; severe intellectual disability typically described where an individual required special educational needs schooling, had limited speech, and would not live independently as an adult.

Protein net charge calculations were undertaken for the wild type and mutant carboxy terminal domain (from p.Lys110 onward) at neutral pH using the Peptide Property Calculator at the Innovagen website and methods as previously described (Tatton-Brown et al., 2017).

**Results**

***Spectrum of HIST1H1E variants***

Thirty unrelated individuals with 14 frameshift *HIST1H1E* variants were identified (Figure 1, Supplementary Table 1). Recurrent variants occurred at c.430dupG\_p.(Ala144Glyfs\*52) (12 patients); c.441dupC\_p.(Lys148Glnfs\*48) (four patients); c.435dupC\_p.(Thr146Hisfs\*50) (two patients) and c.436\_458del23\_p.(Thr146Aspfs\*42) (two patients).

All variants were absent from the gnomAD database, clustered to a 94 base pair region in the carboxy terminal domain (CTD) and were predicted to result in the same shift in the reading frame (Figure 1, Supplementary Figure 1). The predicted mutant proteins shared the same 38 amino acid carboxy terminal motif and all were predicted to have a reduced net positive charge at pH 7 of -6 to 10.9 compared to the predicted wild type protein charge of 41 (Supplementary Figure 1).

***HIST1H1E phenotype***

Phenotype data for the 30 patients, including 13 males and 17 females with ages ranging from nine months to 30 years, are detailed in Supplementary Table 1. Notable themes included a recognizable facial gestalt with abnormal dentition, a consistent intellectual disability often with behavioral problems and associated medical problems including hypotonia, cryptorchidism in boys, congenital cardiac anomalies, hypothyroidism, a range of skeletal anomalies and brain MRI abnormalities (Figure 2).

*Facial Gestalt*

There were shared facial features amongst children and adults with HIST1H1E syndrome (Figure 3). In early childhood, patients had full cheeks and at all ages patients frequently had a high hairline, bi-temporal narrowing, deep set eyes, downslanting palpebral fissures and hypertelorism and often appeared older than their chronological age (Figure 3A and 3B).

*Learning and Behavior*

All 30 patients were described as having an intellectual disability but only 24 patients were old enough to determine their degree of cognitive impairment: 17% (4/24) patients were reported with a severe intellectual disability, 79% (19/24) patients were reported with a moderate intellectual disability and 4% (1/24) patients were reported with a mild intellectual disability. Of note, many families report a particular deficit in expressive language acquisition, discrepant with other cognitive skills such as understanding. In addition, behavioral issues were common (50%; 15/30) and included combinations of anxiety; attention deficit hyperactivity disorder; autistic spectrum disorder/traits; head banging and aggression (Figure 2, Supplementary Table 1).

*Associated Clinical Features*

Hypotonia was a common feature 63% (19/30), frequently presenting in the neonatal period. Brain MRI imaging had been undertaken in 15 patients and was reported abnormal in 13 (86%) with corpus callosum abnormalities the most frequent finding (Figure 2).

Cryptorchidism was reported in in 69% (9/13) of boys. Abnormal dentition including dental erosions, thin enamel, crumbling teeth and multiple dental caries was reported in 43% (13/30) patients (Figure 3C).

Cardiac abnormalities were reported in 43% (13/30) patients, and included combinations of atrial septal defect (nine patients), ventricular septal defect (three patients), patent foramen ovale (one patient), patent ductus arteriosus (one patient) and persistent superior vena cava (one patient). Skeletal anomalies were reported in 40% (12/30) and included combinations of kypho/scoliosis (four patients), camptodactyly (three patients), lower limb asymmetry (two patients) and craniosynostosis, distal brachydactyly, multiple fractures and overlapping toes (one patient each). Hypothyroidism had been diagnosed in five patients (29%, where 17 patients had been tested). Ectodermal abnormalities were reported in six patients including thin and/or brittle, slow growing hair, lack of body hair and thin nails.

*Growth*

The mean birth weight was 0.2 standard deviations above the mean (0.2SD), mean birth length was 0.3SD and the mean birth head circumference was 1.4SD. Postnatally, the mean height was 0.4SD (range of -1.8SD to 8.3SD); the mean weight was 1.1 SD (range of -1.8SD to 4.6SD) and the mean head circumference was 1.1SD (range of -1.7 to 3.7SD) (Figure 4).

**Discussion**

The aim of this study was to define the HIST1H1E syndrome phenotype in order to propose evidence-based management guidance. Through the detailed clinical evaluation of 30 patients with likely/pathogenic *HIST1H1E* variants, we have shown that an intellectual disability (most frequently moderate) and a characteristic facial gestalt are consistent HIST1H1E associations. Other frequent clinical findings include behavioral issues (especially anxiety); cryptorchidism; hypotonia; abnormal dentition; congenital cardiac anomalies; hypothyroidism; ectodermal findings and brain MRI findings (most frequently corpus callosum abnormalities). Contrary to the initial report, height and/or head circumference were not consistently increased >2SD. We propose the name **HIST1H1E** syndrome as an acronym to help remember the characteristic features of this emerging, recognizable phenotype: **H** for Hypotonia, **I** for Intellectual Disability (ID) with behavioral Issues, **S** for Skeletal, **T** for Testes (undescended) and Thyroid, **H** for Heart anomalies and **E** for Ectodermal issues (including sparse hair and abnormal dentition).

Based upon the current phenotypic evaluation, we suggest children with *HIST1H1E* variants are regularly reviewed by a pediatrician to assess development and determine appropriate referral to speech and language therapy and physical therapy; that children have a regular (at least six monthly) dental review to mitigate potentially preventable issues arising from abnormal dentition and that annual thyroid function tests are undertaken. Given the association with congenital cardiac anomalies, we propose a baseline echocardiogram investigation is undertaken with cardiology follow up dependent upon findings. Although *HIST1H1E* somatic variants have been associated with chronic lymphocytic leukemia as well as diffuse large B-cell lymphoma and hepatocellular carcinoma, these are more usually nonsynonymous variants distributed throughout the gene (Chang et al., 2019). None of the patients in this current clinical series developed cancer. We do not therefore currently advocate specific tumor surveillance but any possible tumor related symptoms should be investigated.

The 14 *HIST1H1E* variants identified in the 30 patients, all cluster to 94 base pair region in the CTD tail of HIST1H1E. This replicates our initial finding that HIST1H1E syndrome variants are frameshift variants that generate a mutant protein with the same 38 amino acid tail, the result of the same shift in the reading frame (Tatton-Brown et al., 2017). To date, no patient with the HIST1H1E syndrome phenotype has been described with a *HIST1H1E* whole gene deletion, stop gain variant or frameshift variant that results in an alternate shift in reading frame (the latter is not predicted to be associated with a net reduction in charge, Tatton-Brown et al., 2017). In addition, none *HIST1H1E* frameshift variants reported in gnomAD cluster to the same 94 base pair region, nor do they result in the same shift in frame and the generation of a mutant protein with the common 38 amino acid tail. This suggests that the HIST1H1E syndrome phenotype is attributable to a specific set of variants with a defined effect on the protein. Our current working hypothesis is that, because *HIST1H1E* is a single exon, intronless gene, the *HIST1H1E* variants escape nonsense-mediated RNA decay and the resultant mutant HIST1H1E proteins are characterized by a reduced net positive charge compared to wild type proteins, potentially disrupting the normal binding between positively charged HIST1H1E and negatively charged DNA (Tatton-Brown et al., 2017). Further work is required to investigate this.

An important remaining question that our current study has not been able to answer is whether the underlying *HIST1H1E* genetic variant determines the range and severity of clinical features. Currently too few patients have been identified to perform robust genotype-phenotype analyses. However, as greater numbers of patients with the HIST1H1E syndrome are identified it will be interesting to further clarify the HIST1H1E phenotype, better delineate the spectrum of causative *HIST1H1E* variants and investigate the relationship between genetic variant and clinical presentation.

**Acknowledgements:**

We thank the patients and families for their active participation in this study and the clinicians that recruited them. We acknowledge support from the NIHR RM/ICR Biomedical Research Centre. KT-B is supported by funding from the Child Growth Foundation (GR01/13) and the work was, in part, supported by a Wellcome Trust Award (100210/Z/12/Z). This study makes use of DECIPHER (<http://decipher.sanger.ac.uk>), which is funded by Wellcome. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF‐1009‐003). See Nature PMID:25533962 or [www.ddduk.org/access.html](http://www.ddduk.org/access.html) for full acknowledgement.

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**URLs**

Uniprot: https://www.uniprot.org/

Facebook Parent Support Group: <https://www.facebook.com/hist1h1e/>

Genome Aggregation Database (gnomAD), <https://gnomad.broadinstitute.org/>

HIST1H1E reference transcript, <https://www.ncbi.nlm.nih.gov/nuccore/NM_005321>

OMIM, <https://www.omim.org/>

Protein calculator, <http://pepcalc.com/protein-calculator.php>

SMART: https://smart.embl.de

Protein Atlas (HIST1H1E): https://www.proteinatlas.org/ENSG00000168298-HIST1H1E/tissue

**References**

Tatton-Brown K, Loveday C, Yost S, Clarke M, Ramsay E, Zachariou A, Elliott A, Wylie H, Ardissone A, Rittinger O, Stewart F, Temple IK, Cole T; Childhood Overgrowth Collaboration, Mahamdallie S, Seal S, Ruark E, Rahman N. Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. Am J Hum Genet. 2017 May 4;100(5):725-736. doi: 10.1016/j.ajhg.2017.03.010. PubMed PMID: 28475857; PubMed Central PMCID: PMC5420355.

Fyodorov DV, Zhou BR, Skoultchi AI, Bai Y. Emerging roles of linker histones in regulating chromatin structure and function. Nat Rev Mol Cell Biol. 2018Mar;19(3):192-206. doi: 10.1038/nrm.2017.94. Epub 2017 Oct 11. Review. PubMedPMID: 29018282; PubMed Central PMCID: PMC5897046.

Roque A, Ponte I, Suau P. Post-translational modifications of the intrinsically disordered terminal domains of histone H1: effects on secondary structure and chromatin dynamics. Chromosoma. 2017 Feb;126(1):83-91. doi: 10.1007/s00412-016-0591-8. Epub 2016 Apr 21. Review. PubMed PMID: 27098855.

Song F, Chen P, Sun D, Wang M, Dong L, Liang D, Xu RM, Zhu P, Li G. Cryo-EMstudy of the chromatin fiber reveals a double helix twisted by tetranucleosomal units. Science. 2014 Apr 25;344(6182):376-80. doi: 10.1126/science.1251413. PubMed PMID: 24763583.

Ponte I, Romero D, Yero D, Suau P, Roque A. Complex Evolutionary History of the Mammalian Histone H1.1-H1.5 Gene Family. Mol Biol Evol. 2017 Mar 1;34(3):545-558. doi: 10.1093/molbev/msw241. PubMed PMID: 28100789; PubMed Central PMCID: PMC5400378.

McGinty RK, Tan S. Nucleosome structure and function. Chem Rev. 2015 Mar 25;115(6):2255-73. doi: 10.1021/cr500373h. Epub 2014 Dec 12. Review. PubMed PMID: 25495456; PubMed Central PMCID: PMC4378457.

Walport LJ, Hopkinson RJ, Chowdhury R, Zhang Y, Bonnici J, Schiller R,Kawamura A, Schofield CJ. Mechanistic and structural studies of KDM-catalyseddemethylation of histone 1 isotype 4 at lysine 26. FEBS Lett. 2018Oct;592(19):3264-3273. doi: 10.1002/1873-3468.13231. Epub 2018 Sep 14. PubMedPMID: 30156264; PubMed Central PMCID: PMC6220849.

Takenouchi T, Uehara T, Kosaki K, Mizuno S. Growth pattern of Rahman syndrome. Am J Med Genet A. 2018 Mar;176(3):712-714. doi: 10.1002/ajmg.a.38616. Epub 2018 Jan 31. PubMed PMID: 29383847.

Duffney LJ, Valdez P, Tremblay MW, Cao X, Montgomery S, McConkie-Rosell A, Jiang YH. Epigenetics and autism spectrum disorder: A report of an autism case with mutation in H1 linker histone HIST1H1E and literature review. Am J Med Genet B Neuropsychiatr Genet. 2018 Jun;177(4):426-433. doi: 10.1002/ajmg.b.32631. Epub 2018 Apr 27. Review. Erratum in: Am J Med Genet B Neuropsychiatr Genet. 2019 Jun;180(4):287.

Cole TJ, Wright CM, Williams AF; RCPCH Growth Chart Expert Group. Designing the new UK-WHO growth charts to enhance assessment of growth around birth. Arch Dis Child Fetal Neonatal Ed. 2012 May;97(3):F219-22. doi: 10.1136/adc.2010.205864. Epub 2011 Mar 11.

Chang, S., Yim, S., & Park, H. (2019). The cancer driver genes IDH1/2, JARID1C/ KDM5C,and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Experimental & molecular medicine, 51(6), 66. doi:10.1038/s12276-019-0230-6

**Figure Legends**

**Figure 1.** Protein schematic showing the 94 base pair clustering of the 14 different protein truncating variants (each variant is designated by a red circle)

**Figure 2.** The key clinical features that characterize the HIST1H1E syndrome.

**Figure 3.** **A**) The facial gestalt consists of a high frontal hairline and full lower cheeks in early childhood and, in later childhood and adulthood, affected individuals have a strikingly high frontal hairline, bi-temporal narrowing, frontal bossing and deep-set eyes.
**B)** The evolving facial gestalt in three individuals at ages stated.
**C)** The dental phenotype includes erosions, thin enamel, crumbling teeth and multiple dental caries. Dental X-rays of an adolescent patient demonstrate thin enamel and short dental roots.

**Figure 4.** Growth parameters (with height on x axis and head circumference on y axis) plotted by standard deviation, calculated with reference to UK90 growth data. Although in individual patients, the height and/or head circumference might be increased above two standard deviations, in most patients the growth parameters cluster around the mean.

**Supplementary Figure 1:** Wild type and mutant HIST1H1E (generated by the 14 different *HIST1H1E* frameshift variants) showing the reduction in net charge of the carboxy terminal domain motif (from Lys110) at neutral pH7. Mutant proteins share a common 38 amino acid tail.